Page 9 - Hansa Biopharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study

/PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced results.

United statesUppsala lanLos angelesStanley jordanHansa biopharmaStephanie kenneyTomas lorantPrnewswire hansa biopharmaKlaus sindahlSinai medical centerUppsala university hospitalHmedides clinical trial programEuropean unionEuropean medicines agencyAmerican kidney fundVp global corporate affairs

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data

LUND, Sweden, Oct. 17, 2023 /PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in.

Uppsala lanUnited statesHansa biopharmahansa biopharmaTomas lorantLos angelesHansa biopharmaPrnewswire hansa biopharmaStanley jordanKlaus sindahlStephanie kenneyHmedides clinical trial programUppsala university hospitalSinai medical centerAmerican kidney fundEuropean unionEuropean medicines agency

Comparing Biora Therapeutics (NASDAQ:BIOR) & Sarepta Therapeutics (NASDAQ:SRPT)

Comparing Biora Therapeutics (NASDAQ:BIOR) & Sarepta Therapeutics (NASDAQ:SRPT)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesUnited kingdomSelecta biosciencesHansa biopharmaBiora therapeutics incProgenity incSarepta therapeutics incGenevant sciencesUniversity of floridaDuke universityRoche ltdBiora therapeuticsGet free reportSarepta therapeuticsGiven sarepta therapeutic

Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients

LUND, Sweden, Oct. 11, 2023 /PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in.

United kingdomUnited statesDonato spotaPrnewswire hansa biopharmaMatthew shaulisKlaus sindahlStephanie kenneyHansa biopharmaDrug administrationLicense applicationNasdaq stockholmBiologics license applicationGlomerular filtration rateAntibody mediated rejectedSarepta duchenne muscular dystrophyInvestor relationsm

Hansa Biopharma AB: Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients

Hansa Biopharma AB: Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomDonato spotaKlaus sindahlPrnewswire hansa biopharmaHansa biopharmaMatthew shaulisStephanie kenneyDrug administrationVp global corporate affairsBiologic license applicationNasdaq stockholmBiologics license applicationGlomerular filtration rateAntibody mediated rejectedSarepta duchenne muscular dystrophy